Caris Life Sciences, a top AI-powered precision medicine company, shared new research that shows TET2 clonal hematopoiesis might be used as a biomarker to predict better responses to immune checkpoint therapy in patients with solid tumors. The study, led by Dr. Padmanee Sharma at the James P. Allison Institute at The University of Texas MD Anderson Cancer Center, was published in Cancer Cell and is titled “TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.”
Health Technology Insights: ModMed Appoints Dr. Tomer Lancewicki to Lead AI Healthcare
The research looked into how immune cells with TET2 mutations from clonal hematopoiesis influence tumor immunology and how the body responds to immune checkpoint therapy. Dr. Sharma and postdoctoral fellow Dr. Shelley Herbrich used TET2-mutant lab models to explore the mechanisms that control immune cell activity in the tumor environment. Their experiments showed how these mutations can boost immune activity inside tumors.
Health Technology Insights: Rune Labs Appoints Digital Health Leader Adam Pellegrini to Board of Directors
To check the real-world importance of these findings, the study analyzed data from Caris Life Sciences’ large clinico-genomic database. The team reviewed results for almost 36,000 patients with non-small cell lung cancer and more than 25,000 with colorectal cancer. This approach gave strong support to the idea that TET2 clonal hematopoiesis could be a helpful predictive biomarker for better response to immune checkpoint therapy. The findings show a clear connection between clonal hematopoiesis and how well treatments work in solid tumors, suggesting that CH could be used in the future to guide treatment choices.
Milan Radovich, Ph.D., Senior Vice President and Chief Scientific Officer at Caris, said the study is a big step forward in understanding how clonal hematopoiesis impacts cancer immunology. He noted that this research shows the untapped potential of CH as a way to predict treatment responses and help create better, more personalized therapies.
Dr. Sharma, who is also a professor of Immunology and Genitourinary Medical Oncology at MD Anderson and director of scientific programs for the Allison Institute, called the results very promising. She explained that TET2-mutated clonal hematopoiesis could help find patients who are most likely to benefit from immunotherapy, offering a new way to approach precision oncology and tailor treatments to individual patients.
Health Technology Insights: Medix and Medix Technology Join Workday Partner Program to Provide HCM and Financial Solutions for Healthcare Clients
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
